Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.

Genes were considered significantly modulated by etrolizumab if they had an absolute fold change ≥ 1.5, at an FDR of < 0.05 in the combined colonic and ileal analysis, and were nominally significant (unadjusted p value < 0.05) in both the colonic- and ileal-only analyses.

also in 7,164 other papers